Advertisement
Document › Details
Sanofi S.A.. (1/19/18). "Press Release: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee". Paris.
Organisation | Sanofi S.A. (Euronext: SAN, Nasdaq: SNY) | |
Group | Sanofi (Group) [since May 2011] | |
Organisation 2 | Ernst & Young (Group) | |
Product | pharmaceutical | |
Product 2 | consulting, business | |
Person | Carouge, Dominique (Sanofi 201802– EVP Head of Business Transformation joined Sanofi 2009 before Ernst & Young) | |
Sanofi has appointed Dominique Carouge as Executive Vice President Head of Business Transformation, effective February 15, 2018. In this role, Mr. Carouge will be in charge of accelerating the transformation of the Company and will be a member of the Executive Committee. He has served as Deputy CFO and Head of Finance Operations and Group Controlling since January 1st, 2016.
Mr. Carouge previously served as Vice-President, Administration & Management for Global R&D since 2011. Prior to that, Mr. Carouge held the role of VP, Chief Strategy and Finance Officer for Sanofi Pasteur since 2009.
Mr. Carouge started his career in 1985 as an external auditor at Ernst & Young (EY) both in France (Paris) and in the US (Philadelphia). He joined Sanofi in 1991. Since then and for the past 27 years, he held various finance positions of increasing responsibility and leadership across Australia, New Zealand, Germany and France.
A citizen of France, Mr. Carouge graduated from "Ecole Supérieure de Commerce de Reims". He also holds a CPA degree in France, as well as a Corporate Governance and Board management certificate from Sciences Po (Certificat d'Administrateur de Sociétés).
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Media Relations
Laurence Bollack
Tel. : +33 (0)1 53 77 46 46
mr@sanofi.com
Investor Relations
George Grofik
Tel. : +33 (0)1 53 77 45 45
ir@sanofi.com
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Record changed: 2023-06-05 |
Advertisement
More documents for Sanofi (Group) [since May 2011]
- [1] Eligo Bioscience S.A.. (12/5/23). "Press Release: Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines". Paris....
- [2] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
- [3] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
- [4] Sanofi S.A.. (8/4/22). "Press Release: Sanofi and Innovent Biologics Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China". Paris....
- [5] BeiGene, Ltd.. (7/13/22). "Press Release: BeiGene Appoints Chan Lee as General Counsel". Cambridge, MA, Basel & Beijing....
- [6] Glycomine, Inc.. (7/11/22). "Press Release: Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors". San Carlos, CA....
- [7] Sanofi S.A.. (3/29/22). "Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets". Paris....
- [8] Sanofi S.A.. (12/1/21). "Press Release: Sanofi to Acquire Origimm Biotechnology in First Move to Treat Acne with Vaccine-based Immunotherapy". Paris & Vienna....
- [9] CRISPR Therapeutics AG. (10/14/21). "Press Release: CRISPR Therapeutics Announces Transition of Chief Financial Officer". Zug & Cambridge, MA....
- [10] MoonLake Immunotherapeutics AG. (8/10/21). "Press Release: MoonLake Immunotherapeutics Appoints Former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors". Zug....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top